GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (FRA:SFY) » Definitions » Debt-to-Equity

Theriva Biologics (FRA:SFY) Debt-to-Equity : 0.06 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Theriva Biologics Debt-to-Equity?

Theriva Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.52 Mil. Theriva Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.34 Mil. Theriva Biologics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €31.39 Mil. Theriva Biologics's debt to equity for the quarter that ended in Mar. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Theriva Biologics's Debt-to-Equity or its related term are showing as below:

FRA:SFY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.05   Max: 0.08
Current: 0.06

During the past 13 years, the highest Debt-to-Equity Ratio of Theriva Biologics was 0.08. The lowest was 0.01. And the median was 0.05.

FRA:SFY's Debt-to-Equity is ranked better than
69.93% of 1074 companies
in the Biotechnology industry
Industry Median: 0.145 vs FRA:SFY: 0.06

Theriva Biologics Debt-to-Equity Historical Data

The historical data trend for Theriva Biologics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Debt-to-Equity Chart

Theriva Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.06 0.02 0.03 0.05

Theriva Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.05 0.05 0.06

Competitive Comparison of Theriva Biologics's Debt-to-Equity

For the Biotechnology subindustry, Theriva Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Debt-to-Equity falls into.



Theriva Biologics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Theriva Biologics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Theriva Biologics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theriva Biologics  (FRA:SFY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Theriva Biologics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Theriva Biologics (FRA:SFY) Business Description

Traded in Other Exchanges
Address
9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics (FRA:SFY) Headlines

From GuruFocus

SOFI WEALTH, LLC Goes on Buying Spree in 2nd Quarter

By GuruFocus Research GuruFocus Editor 07-25-2022